
Commentary|Videos|April 3, 2025
PRO Data for Mirvetuximab Soravtansine From MIRASOL in FRa+ Platinum-Resistant Ovarian Cancer
Fact checked by: Chris Ryan
Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, on patient-reported outcome data for mirvetuximab soravtansine in platinum-resistant ovarian cancer.
Advertisement
Episodes in this series

Advertisement
Related to this article

The top 5 OncLive TV videos of the week cover insights in HER2+ breast cancer, NSCLC, ovarian cancer, prostate cancer, and sarcoma.

Retrospective data tie longer survival with niraparib maintenance to homologous recombination deficiency after complete primary debulking.

Exploratory BEHOLD-1 data show responses to mocertatug rezetecan in platinum-resistant ovarian cancer across B7-H4 expression levels.

Updated BEHOLD-1 data show mocertatug rezetecan at its selected dose produced lasting responses in platinum-resistant ovarian cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Removes Limitations of Use for Liso-Cel in Primary Central Nervous System Lymphoma
2
FDA Accepts sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis
3
Beyond the Target: Payloads, Therapeutic Windows, and Biomarkers Shape the Next Wave of ADCs in NSCLC
4
Sintilimab Receives Positive CHMP Opinion for First-Line Nonsquamous NSCLC
5

